Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

share with twitter share with LinkedIn share with facebook
09/14/2020 | 07:41am EDT

Sept 14 (Reuters) - Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

The U.S. drugmaker said the drug, in combination with Gilead Sciences Inc's remdesivir, met the main goal of shortening recovery when compared to remdesivir alone. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)


Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -0.25% 131.31 Delayed Quote.0.11%
GILEAD SCIENCES, INC. -3.18% 58.72 Delayed Quote.-10.59%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
11:16aGLOBAL MARKETS LIVE : Microsoft, Deutsche Bank, Sony…
10/26ELI LILLY AND : NIH Halts Study Exploring Treating Covid-19 With Lilly Antibody,..
DJ
10/26ELI LILLY AND : NIH Halts Study Exploring Treating Covid-19 With Lilly Antibody,..
DJ
10/26GILEAD SCIENCES : Completes Acquisition of Immunomedics, Inc.
AQ
10/26LIGAND PHARMACEUTICALS INCORPORATED : Captisol Technology Plays Key Role in the ..
AQ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/24GILEAD SCIENCES : Mexico will not follow FDA in approving Gilead's COVID-19 drug
RE
10/23Stocks mixed; COVID-19 vaccine trials to restart
RE
10/23GILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other ..
AQ
10/23S&P, Nasdaq close higher as stimulus talks in spotlight
RE
More news
Financials (USD)
Sales 2020 24 037 M - -
Net income 2020 2 282 M - -
Net Debt 2020 14 558 M - -
P/E ratio 2020 35,8x
Yield 2020 4,50%
Capitalization 73 619 M 73 619 M -
EV / Sales 2020 3,67x
EV / Sales 2021 3,53x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 77,29 $
Last Close Price 60,01 $
Spread / Highest target 75,0%
Spread / Average Target 28,8%
Spread / Lowest Target -5,02%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.59%75 236
REGENERON PHARMACEUTICALS50.42%61 299
VERTEX PHARMACEUTICALS-3.97%55 269
WUXI APPTEC CO., LTD.64.97%39 253
BEIGENE, LTD.81.31%27 327
GENMAB A/S48.84%22 921